cyrilzakka/clinical-trials huggingface dataset:
Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes: A Prospective Community-based (Workplace) Cohort Study

This study aimed to evaluate the effectiveness of use of Continuous Glucose Monitoring (CGM), combined with personalized dietary education and use of smartphone applications in improving glucose control and weight management.


Eligibility Criteria:
Inclusion Criteria:

* Subjects over the age of 19
* Patients with type 2 diabetes

  * Fasting blood glucose ≥ 126 mg/dL or
  * HbA1c ≥ 6.5% or
  * Type 2 diabetes by clinical history and treated with antidiabetic medications or lifestyle Modifications
* Patients with prediabetes

  * Fasting blood glucose 100-125 mg/dL
  * HbA1c 5.7-6.4%
* Willing to participate in the study

Exclusion Criteria:

* Subjects less than 19 years old
* Patients with type 1 diabetes
* Pregnant at the time of screening or planning to become pregnant during the study
* Severe chronic diseases such as cancer, stroke, proliferative retinopathy, myocardial infarction, chronic renal disease, or amputation of a diabetic foot
* Diagnosed with or treated for myocardial infarction, stroke, end-stage renal disease, liver failure, or chronic lung disease within the past year
* Severe liver disease (e.g., cancer, liver cirrhosis, hepatitis B, hepatitis C)
* Diseases of the biliary tract, thyroid disorders, autoimmune disorders, or acute infections
* Planning to be admitted to a hospital within 2 months
* Unable to participate in the mobile intervention study as determined by the investigator
Value Of ACE Index (Albumin, CRP And Endoscopy) In Predicting Intra Venous Steroid Response In Acute Severe Ulcerative Colitis In Assiut University Hospitals

1. Determine if the ACE index can predict resoponse to I V steroid in Acute severe ulcerative colitis
2. identify on admission a high-risk population who may beneft from earlier second line medical treatment or surgical intervention. ( steroid non responder groups )

UlCerative colitis is characterized by mucosal inflammation initiating in the rectum and extending proximally in the colon in a continuous fashion. In patients with acute severe colitis, prompt hospital admission is required, A multidisciplinary approach is fundamental, and contacting a colorectal surgeon at the moment of admission is recommended. Sometimes, emergency surgery might be required early on in case of toxic megacolon, perforation or massive bleeding.

Although treatment initiation should not be postponed in severe cases, excluding differential diagnoses, including C. difficile infection, is crucial. A limited flexible sigmoidoscopy without bowel preparation should be performed to assess disease severity .(1) aggressive medical therapy, starting with intravenous corticosteroids. Intravenous \[IV\] steroids remain the frst-line medical therapy for patients admitted with acute severe UC \[ASUC\], as defned by Truelove and Witts criteria,)(2) Almost one-third of patients, however, may not respond to IV steroids and go on to require second-line medical therapies \[primarily inﬂiximab or ciclosporin\] or a colectomy .

A signifcant body of research in recent years has focused on predicting outcome in patients with ASUC treated with IV steroids; ,(3) In 2022 the novel ACE was reported \[Albumin, CRP, and Endoscopy\] Index in acute colitis, which used biochemical and endoscopic parameters to predict steroid non-response on admission (albumin ≤ 30g/L \[0 or 1\] + C-reactive protein \[CRP\] ≥ 50 mg/L \[0 or 1\] + endoscopically severe according to physician's global assessment component of the Mayo score \[0 or 1\]), We can identify a high-risk subset of patients for targeted counselling and early administration of second-line therapy; this is particularly crucial as treatment delays are associated with increased mortality.

Eligibility Criteria:
Inclusion Criteria:

- Adult Patients (≥18 years) known ulcerative colitis presented with activity .

2- newly diagnosed ulcerative colitis

Exclusion Criteria:

* 1) patient presented with CMV colitis 2) Clostridium difficile infection 3) Elective admission
Effects of Recorded Music on Clinical and EEG Seizure Activity

This research is being done to determine if Mozart music and/or age-appropriate music can reduce the frequency of seizures and epileptiform discharges.

Several prospective studies have demonstrated the impact of Mozart's sonata for Two Pianos (K.448) on interictal epileptiform discharges and/or clinical seizure recurrence in children with epilepsy. While the exact mechanisms by which Mozart music has this effect are not yet established, there continues to be growing evidence demonstrating the positive effects on Mozart music upon seizure frequency and epileptiform discharges. Additional studies are needed to further elucidate the effect of Mozart music on epilepsy given the heterogeneity of protocols used in diverse clinical settings, with the goal of using these findings to drive potential therapy in the clinical setting.

Therefore, this study will explore if there are differences in epileptiform activity and clinical seizures between Mozart K.448, instrumental age-appropriate songs, and a patient's baseline activity during EMU stays. The children (age 4-17 yrs.) will listen to Mozart K.448 (1st movement) and instrumental age-appropriate songs with washout (10 minutes) in between, each lasting up to 9 minutes in the daytime. The music stimuli will be randomly played in 2 to 7 EMU stay days (average length of stay 4 days) and delivered via single-use earbuds. As per standard clinical care the investigators will monitor continuous video electroencephalography (EEG) in the epilepsy monitoring unit.

The frequency of epileptiform discharges (e.g., the number of spikes per 100 seconds, the number of seconds with spikes, and clinical seizures) will be counted before, during, and after music procedures. Heart rate variability and blood pressure will also be measured before, during, and after music stimuli to understand associations between physiological responses and epileptiform discharges to musical stimuli. Participants' behavior changes will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Children (age: 4 - 17 years old) who stay at Epilepsy Monitoring Units (EMU) up to 7 days may join.

Exclusion Criteria:

* Non-English Speaking
Evaluation of Predictive Visual Analog Scale (VAS) for Determining the Ingesta of Patients Carrying a Digestive Cancer

The main objective of our study is to determine if the evaluation of ingesta of cancer patients by VAS (on the day of hospitalization) is able to predict the actual ingesta of patients during hospitalization (for patients malnourished, at risk of malnutrition or risk free).


Eligibility Criteria:
Inclusion Criteria:

* Patients aged over 18 years
* Admitted to hospital for systemic therapy of gastrointestinal cancer
* Signature of the non-opposition.

Exclusion Criteria:

* Patients who because of their affection will fasted more than 12:00 during the three days preceding hospitalization.
* Artificial nutrition Patients
Pulmonary Nodule Localization Prospective Validation

Localization is the key for successful excision of small target nodules under thoracoscopy, but the procedure also brings risks to patients. However, the criteria is still unclear. The investigators will validate the prediction model produced by institutional retrospective analysis in the prospective cohort.

Excision of targeted lung nodules during thoracoscopy sometimes needs placing a mark before surgery. The procedure of mark placement (localization) could probably cause damages to the patients. However, the criteria for patient selection is still not clear. Through respective analysis, the investigators have set up a prediction model and wish to validate this model prospectively.

Eligibility Criteria:
Inclusion Criteria:

* Age ≧ 20 years
* Lung nodule size ≦2cm on the pre-operative computed tomography (CT)
* Nodulectomy is performed under thoracoscopy

Exclusion Criteria:

* Age \< 20 years
* Lung nodule size \> 2cm on CT or in the final pathology report
* Open surgery for nodulectomy
Comparing Pleth Variability Index (PVI) Measurements at Different Sensing Locations

The purpose of this study is to assess the suitability of the ear and forehead as a better site for measure of fluid responsiveness.

The aim of this study is to compare Pleth Variability Index (PVI) measurements at different sensor locations in respect to signal quality, sensor fit to site location and fluid responsiveness. PVI will be measured at 3 different sensor sites: the fingers, ear lobes and forehead. The ability to predict fluid responsiveness will be analyzed using cardiac output as the reference value.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Undergo any type of surgeries under general anesthesia in UCI Medical Center
* Mechanically ventilated during surgery
* Arterial line placement is preferred but not required
* Agree to sign the consent and HIPAA forms

Exclusion Criteria:

* Less than 18 years of age
* Pregnant women
* Refused to sign the consent and HIPAA forms
* Receive vasoactive medication prior to surgery
* Has these conditions: hypotension, hypothyroidism, moderate or poorly controlled hypertension, chronic poorly-controlled diabetes, heart failure patients, and patients with active airway flow obstruction, left ventricular dysfunction, intra-cardiac shunts, right ventricular dysfunction, atrial fibrillation, arrhythmias
* patients with surgeries at or around site of sensor placement
* Subject has skin abnormalities affecting the digits such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, nail polish or acrylic nails that would prevent monitoring of SpO2 levels during the study
Comparing Articaine and Mepivacaine Without Palatal Injection in Pain Assessment During Maxillary Teeth Extraction

This study compares the the efficacy of buccal infiltration of 4% Articaine and 2% Mepivacaine without any palatal injection during extraction of maxillary teeth. One group of patient receives buccal infiltration of Articaine and another group receives buccal infiltration of Mepivacaine.

Dense local anesthesia is required to reduce pain during extraction of tooth. Administration of local anesthesia to the palatal mucosa is proved to be the most painful due to its firm adherence to the underlying periosteum and also it's abundant nerve supply. Articaine has greater lipid solubility and high bone penetration property. Mepivacaine is proven to be the safest local anaesthetic agent. Avoidance of a palatal injection during extraction will benefit the patient by reducing pain and anxiety to a greater extent.

So this study compares the bone penetration property between Articaine and Mepivacaine by assessing the pain in the palatal mucosa while extracting the tooth using only buccal infiltration.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years and above
* Patients requiring extraction of maxillary teeth which are grossly decayed, grade I mobile, root stumps or indicated for therapeutic extractions.
* Healthy patients ( ASA I ) or patients with mild systemic disease with no functional limitations (ASA II).
* Patients who are not allergic to the drugs used in the study

Exclusion Criteria:

* Patients with periapical infections.
* Patients who are on concurrent treatment with NSAIDs and corticosteroids
Pilot Trial of Mobile Mantram Delivery

Mantram Repetition Program (MRP) is a meditation practice that involves silent repetition of a spiritual word, one-pointed attention, and slowing down. It has been shown to help reduce PTSD symptoms among Veterans. This study will look at how Veterans reach to learning MRP via the Internet, either in a self-directed way or with text/phone support.

Easily accessible interventions to address post-traumatic stress disorder (PTSD) can play critical role in reducing PTSD and associated symptoms in Veterans, especially for those who remain symptomatic after treatment with other evidence-based interventions, those who prefer complimentary and integrative therapies, or those who have difficulty accessing traditional face-to-face mental health services. The value of these programs is their ability to provide Veterans with more options in their recovery journey and to reach a broad range of Veterans across multiple settings, including remote rural contexts.

The Mantram Repetition Program (MRP) is a meditation-based practice that consists of the repetition of a spiritual word, one-pointed attention, and slowing down. MRP has been shown to reduce stress in several high-risk populations, and two large randomized, controlled studies show that MRP reduces PTSD symptoms among Veterans. A brief, web-based, self-directed version of MRP has been developed to increase the accessibility of evidence-based PTSD treatment. This version of MRP was tested in a pilot study with undergraduate students, demonstrating its ease of use and success in getting students to engage with the practice. The proposed mixed method study will use the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to evaluate the mobile MRP in Veterans with PTSD in two conditions: self-directed and with text/phone support. Data from this pilot study will inform the refinement of the MRP delivery strategy and the development of a full-scale trial to test its effectiveness and implementation outcomes, as well as barriers and facilitators, and other contextual factors.

Eligibility Criteria:
Inclusion Criteria:

* Veteran
* Primary clinical complaint of PTSD
* Access to an Internet-enabled device

Exclusion Criteria:

* Cognitive impairment or mental health concerns that necessitated a higher level of care or interfered with ability to engage in study activities
Chronic Obstructive Pulmonary Disease Markers and Prognosis

The study aim is to verify the association between the changes in markers of disease and patient´s prognosis in chronic obstructive pulmonary disease.

In a previous study, 133 COPD patients were followed-up during the period of one-year. Analyses of the association between baseline characteristic and the occurence of disease exacerbation was performed. In this study, the patients included in the previous research will be contacted and invited to participate in a complete evaluation after a three-year period. The association of the changes in dyspnea perception, spirometry variables, body composition, quality of life and exercise tolerance measures with disease prognostic will be studied.

Eligibility Criteria:
Inclusion Criteria:

* COPD diagnosis according to the GOLD criteria

Exclusion Criteria:

* Asthma
* Inability to perform pulmonary function and exercise tolerance tests
* Recent myocardial infarction or unstable angina
* Congestive heart failure: class III/IV
The Benefit of Autologous Blood Transfusion in Total Hip Arthroplasty

The investigators studied the benefit of preoperative autologous blood donation in participants who undergo total hip arthroplasty. Study is made as a prospective and randomized.

Total hip arthroplasty is procedure followed with large perioperative and postoperative blood loss. In order to avoid the application of large amounts of allogeneic blood, preoperative autologous blood donation as a tipe of autologous transfusion have been developed.

In this study, the investigators studied the benefit of preoperative autologous blood donation in participants who undergo total hip arthroplasty. Study is made as a prospective and randomized.

Participants were divided into three groups: the first group donated one dose of autologous blood 14 days preoperatively, the second group donated one dose of autologous blood 72 hours preoperatively and a third group was not donated autologous blood.

The blood parameters, hemodynamic stability, bleeding, the need for application of autologous or homologous blood and length of hospital stay were compared.

Eligibility Criteria:
Inclusion Criteria:

* subject older than 18 years
* subject has primary coxarthrosis
* subject has indication for total hip replacement

Exclusion Criteria:

* subject has secondary coxarthrosis
* subject has need for revision endoprosthesis
* history of autoimmune, malignancy or coagulation disorder
* history of myocardial infarct or cerebrovascular insult in last 6 months
* history of angina pectoris and unregulated hypertension
* history of renal or liver failure
AdvisaTM IPG Clinical Evaluation Study

The purpose of the Advisa IPG clinical study is to evaluate the overall system safety and clinical performance of the Advisa DR Implantable Pulse Generator (IPG).

The Advisa IPG is an investigational dual chamber pacemaker that provides rate-responsive bradycardia pacing and diagnostics and atrial tachycardia detection and therapy.

The study will be a prospective, non-randomized, multicenter clinical study, conducted.

To allow for sufficient experience with the device, a maximum of 80 subjects may be implanted with the Advisa device. Data will be collected at baseline (enrollment), implant, 1-, 3- and 6- months post implant and every 6 months thereafter or until study closure (whichever occurs first), unscheduled follow-up visits, System Modifications, Technical Observations, Study Deviations, Study Exit, upon notification of new or updated Adverse Events and in case of death.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have an IPG indication for implantation of a dual chamber pacemaker.
* Patients who are geographically stable and available for follow-up at the study center for the duration of the study.
* Patients who have signed a Medical Ethics Committee (MEC) approved Informed Consent form.

Exclusion Criteria:

* Patients with a life expectancy less than the duration of the study.
* Patients with a Class III indication for permanent pacing according to ACC/AHA/NASPE 2002 guidelines.
* Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients.
HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences


Eligibility Criteria:
Inclusion Criteria:

* All patients having received at least one infusion of HepaStem during a previous interventional clinical study conducted by Promethera.

Exclusion Criteria:

* Patients who received an OLT and completed 6-month FU documentation prior to the start of the PROLONGSTEM study.
* Patients who have received mature liver cells or stem cells other than HepaStem prior to the start of the PROLONGSTEM study.
Usage of Health Information Exchange (HIE) Technologies

The purpose of this research study is to describe the usage of consumers and providers when using a novel technology designed to give consumers the ability to manage and access their health information. This is a quantitative descriptive analysis study.

New York State has awarded grants to several regional health information exchange organizations (RHIOs), organizations established to create the technical and policy infrastructure needed to exchange health data between providers, payers, and public health agencies within a particular geographic region, to build an interoperable system for people to manage their own health information. Two of these grant recipients are the Brooklyn Health Information Exchange (BHIX) and Long Island Patient Information Xchange (LIPIX).

Since no off-the shelf technology currently exists to create such a system, BHIX is working with a commercial vendor to develop a unique system that is tailored toward the needs of their consumers and providers, while LIPIX is developing their own unique system in-house. Both BHIX's and LIPIX's interoperable personal health management systems will offer various features to consumers and providers in their community. Consumers may be able to perform tasks such as viewing their lab results, scheduling an appointment, or sending a message directly to their physician through a SMS. Conversely, the PHR can also allow physicians to engage in communications with their patient, release data to their patient(s) (e.g. lab test result); and view patient inputted-data.

The usage patterns of these personal health managements systems is not well understood (Ralson et al., 2009; Kim et al., 2007). Understanding consumers and providers' use of these interoperable systems can help aid in improving current systems and developing future systems.

Specific Aims

The specific aims of this study are to describe the usage of BHIX's and LIPIX's novel interoperable personal health management systems, specifically:

1. To quantify adoption of and frequency of use of novel technological platforms designed to give consumers (patients) access to RHIO-based health information exchange (HIE) data;
2. To quantify usage of HIE-specific data elements within these platforms;
3. To explore associations between usage and user demographics/clinical characteristics;
4. To explore trends in usage over time.

Eligibility Criteria:
Inclusion Criteria:

* Consumers: Consumers (patients or their designated proxies)who are 18 years of age or older and who have registered for either BHIX's personal health record system or LIPIX's secure messaging system.
* Providers: Healthcare Providers who are authorized to view Health Information Exchange data of BHIX or LIPIX.

Exclusion Criteria:

* Anyone that does not fall into the above inclusion category.
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.

A retrospective study, involving the first fifty patients treated with tocilizumab for acute deterioration in COVID-19 pneumonia in the Intensive Care Unit (ICU) at Mater Dei Hospital in Malta.

The following parameters will be collected from medical records:

* procalcitonin levels, daily for twenty days or until discharge or death.
* namely white cell count (WCC), neutrophils, lymphocytes,
* C-reactive protein (CRP)
* PaO2/FiO2 ratio (P/F ratio).

This group will be compared to a control group was chosen from patients admitted to the ICU who were not eligible for tocilizumab treatment, matched to the study group for age, gender, mode of ventilation required and length of stay in ICU.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed COVID-19 diagnosis
* Admitted to ITU
* Tocilizumab treatment

Exclusion Criteria:

* none
A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)

This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by sibutramine.


Eligibility Criteria:
Inclusion Criteria:

* Subject is a male between 18 and 45 years of age
* Subject has a body mass index (BMI) between 28 and 35 kg/m\^2
* Subject does not weigh more than 140 kg (309 lbs) at the screening visit
* Subject is right-handed
* Subject is a non-smoker
* Subject is in generally good health
* Subject has normal or corrected to normal vision

Exclusion Criteria:

* Subject works a night shift within 3 days of each treatment visit
* Subject has permanent cosmetic or metallic objects in his body
* Subject has attention deficit hyperactivity disorder (ADHD)
* Subject has or had sleep apnea
* Subject has a history of neurological disorders
* Subject has a history of any clinically significant disease or condition
* Subject is vegan or vegetarian
* Subject has a history of eating disorders
* Subject has had previous bariatric surgery